

Xueqiong Wu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1865936/publications.pdf>

Version: 2024-02-01

34
papers

592
citations

758635

12
h-index

676716

22
g-index

35
all docs

35
docs citations

35
times ranked

516
citing authors

#	ARTICLE	IF	CITATIONS
1	The current status, challenges, and future developments of new tuberculosis vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1697-1716.	1.4	81
2	Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy. <i>Frontiers in Microbiology</i> , 2021, 12, 745592.	1.5	60
3	Development of efflux pump inhibitors in antituberculosis therapy. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 421-429.	1.1	41
4	Peptide-Based Vaccines for Tuberculosis. <i>Frontiers in Immunology</i> , 2022, 13, 830497.	2.2	37
5	Peptides-Based Vaccine MP3RT Induced Protective Immunity Against Mycobacterium Tuberculosis Infection in a Humanized Mouse Model. <i>Frontiers in Immunology</i> , 2021, 12, 666290.	2.2	32
6	COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials. <i>Expert Review of Vaccines</i> , 2021, 20, 857-880.	2.0	32
7	Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic. <i>International Reviews of Immunology</i> , 2022, 41, 283-296.	1.5	29
8	Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis. <i>BioMed Research International</i> , 2020, 2020, 1-21.	0.9	28
9	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
10	Polymorphisms in the Interleukin 18 Receptor 1 Gene and Tuberculosis Susceptibility among Chinese. <i>PLoS ONE</i> , 2014, 9, e110734.	1.1	20
11	Latent tuberculosis infection amongst new recruits to the Chinese army: Comparison of ELISPOT assay and tuberculin skin test. <i>Clinica Chimica Acta</i> , 2009, 405, 110-113.	0.5	18
12	Role of calcium channels in cellular antituberculosis effects: Potential of voltage-gated calcium-channel blockers in tuberculosis therapy. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 471-476.	1.5	15
13	Immunogenicity and therapeutic effects of a Mycobacterium tuberculosis rv2190c DNA vaccine in mice. <i>BMC Immunology</i> , 2017, 18, 11.	0.9	13
14	Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?. <i>Indian Journal of Tuberculosis</i> , 2021, 68, 401-404.	0.3	13
15	A peptide-based vaccine ACP derived from antigens of Mycobacterium tuberculosis induced Th1 response but failed to enhance the protective efficacy of BCG in mice. <i>Indian Journal of Tuberculosis</i> , 2022, 69, 482-495.	0.3	13
16	Association of Mannose-binding Lectin Polymorphisms with Tuberculosis Susceptibility among Chinese. <i>Scientific Reports</i> , 2016, 6, 36488.	1.6	12
17	Immunogenicity and Therapeutic Effects of Latency-Associated Genes in a Mycobacterium Tuberculosis Reactivation Mouse Model. <i>Human Gene Therapy Methods</i> , 2019, 30, 60-69.	2.1	11
18	Immunogenicity and Therapeutic Effects of pVAX1-rv1419 DNA from Mycobacterium tuberculosis. <i>Current Gene Therapy</i> , 2016, 16, 249-255.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Ag85A/ESAT-6 chimeric DNA vaccine induces an adverse response in tuberculosis-infected mice. <i>Molecular Medicine Reports</i> , 2016, 14, 1146-1152.	1.1	10
20	Advances in Key Drug Target Identification and New Drug Development for Tuberculosis. <i>BioMed Research International</i> , 2022, 2022, 1-23.	0.9	10
21	Evaluation of a Tuberculosis Whole-Blood Interferon- γ Chemiluminescent Immunoassay among Chinese Military Recruits. <i>Molecular Diagnosis and Therapy</i> , 2011, 15, 341-346.	1.6	9
22	Latent tuberculosis infection among new recruits to the army in Beijing, China in 2009. <i>Apmis</i> , 2011, 119, 377-384.	0.9	9
23	Evaluation of a whole-blood chemiluminescent immunoassay of γ -IFN, γ -IP γ , and MCP γ for diagnosis of active pulmonary tuberculosis and tuberculous pleurisy patients. <i>Apmis</i> , 2016, 124, 856-864.	0.9	9
24	Therapeutic effects of traditional Chinese medicine Niubeixiaohe in mouse tuberculosis models. <i>Journal of Ethnopharmacology</i> , 2017, 195, 318-323.	2.0	9
25	Identification of Rifampin-Resistant Genotypes in <i>Mycobacterium tuberculosis</i> by PCR-Reverse Dot Blot Hybridization. <i>Molecular Biotechnology</i> , 2009, 41, 1-7.	1.3	8
26	Immunotherapeutic effects of <i>Mycobacterium tuberculosis</i> rv3407 DNA vaccine in mice. <i>Autoimmunity</i> , 2018, 51, 417-422.	1.2	8
27	An alert of <i>Mycobacterium tuberculosis</i> infection of rhesus macaques in a wild zoo in China. <i>Experimental Animals</i> , 2017, 66, 357-365.	0.7	7
28	A new method of screening for latent tuberculosis infection: Results from army recruits in Beijing in 2014. <i>Immunology Letters</i> , 2017, 186, 28-32.	1.1	5
29	Immunogenicity and therapeutic effects of recombinant Ag85AB fusion protein vaccines in mice infected with <i>Mycobacterium tuberculosis</i> . <i>Vaccine</i> , 2017, 35, 3995-4001.	1.7	5
30	Immunogenicity and therapeutic effects of pVAX1- rv1419 DNA from <i>Mycobacterium tuberculosis</i> . <i>Current Gene Therapy</i> , 2016, , .	0.9	4
31	Novel epitopes identified from <i>Mycobacterium tuberculosis</i> antigen Rv2629 induces cytotoxic T lymphocyte response. <i>Immunology Letters</i> , 2018, 203, 21-28.	1.1	3
32	Chinese Traditional Medicine NiuBeiXiaoHe (NBXH) Extracts Have the Function of Antituberculosis and Immune Recovery in BALB/c Mice. <i>Journal of Immunology Research</i> , 2021, 2021, 1-20.	0.9	3
33	Prediction and analyses of HLA-B*57:01 restricted <i>Mycobacterium tuberculosis</i> CD4 + T cell epitopes in the Chinese population. <i>Biotechnology and Applied Biochemistry</i> , 2021, , .	1.4	2
34	Comparison of Three Cellular Immunoassays to Detect Tuberculosis Infection in 876 Healthy Recruits. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 547-553.	0.5	0